The purpose of this study is to evaluate the use of an injectable combination of bupivacaine and meloxicam (Zynrelef) vs injectable liposomal bupivacaine (Exparel), two extended local anesthesia strategies currently approved by FDA and on the market for post-surgical pain control. The investigators plan on randomizing study participants to either Exparel or Zynrelef at the closure site of robotic sleeve gastrectomy and assessing their pain control postoperatively both in the hospital and at home. The investigators will measure the outcome of two drugs, Zynrelief, and Exparel on postoperative pain score -using the NRS pin score up to 72 hours after surgery. The total opioid use will be recorded in forms that will be used to measure pain score and total opioid use and will be collected to the Excel sheet. The cost of the drug will be calculated for internal use for Hospital purpose only.
Age range: 18-65 years old
Scheduled or being scheduled to undergo robotic sleeve gastrectomy by Dr. Goyal.
Is able to provide written informed consent.
Is able to adhere to the study visit schedule and complete all study assessments.
Positive urine drug screen prior to surgery
History of substance abuse in the past year-by self report
Patient with ongoing daily narcotic use at the time of surgery-by self report
Inability to understand informed consent or read English/Spanish
Parallel
Zynrelef
DrugZynrelef will be injected at the 12mm port site
Exparel
DrugExparel will be injected at the 12mm port site
postoperative pain score
this will be measured using a numerical rating scale. The scale is 0-10 with 0 being no pain and 10 being the worst pain of their life
Total postoperative opioid use
total amount of pain medications used postoperatively converted into morphine equivalents
Proportion of total rescue medication use
the amount of times a rescue medication had to be used
Click on the lead sponsor to view all of their trials.
